All In Biotech

Drug Trial Radar · NCT07933419

Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors

A Phase Ib/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenous QLS5133 Combination Therapy in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

558

Planned (sponsor's estimate)

Start

Nov 15, 2026

Primary completion

Nov 15, 2027

Study completion Nov 15, 2029

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5133 (injectable) in combination with other therapies for participants with advanced solid tumors. This is a multicenter, open-label study consisting of two parts: dose escalation and tumor-specific expansion. The main questions it aims to answer are: * In the dose-escalation part: What is the safety, tolerability, PK profile, and preliminary efficacy of QLS5133 combination therapy, and what are the recommended dose(s) for expansion? * In the expansion part: What is the anti-tumor efficacy and further safety profile of QLS5133 combination therapy at the selected dose(s) in participants with specific tumor types? Participants will: * Be enrolled in sequential cohorts to receive QLS5133 in combination with other anticancer agents. * Undergo regular assessments for safety, drug concentration levels (PK), and tumor response.

Conditions

  • Clear Cell Renal Cell Carcinoma
  • Ovarian Cancer
  • Other Advanced Solid Tumors

Interventions

  • QLS5133; Lenvatinib mesylateDrug

    QLS5133: Intravenous infusion, Q3W; Lenvatinib mesylate: Oral, once daily

  • QLS5133; QL2107; Lenvatinib mesylateDrug

    QLS5133 and QL2107: Intravenous infusion, Q3W; Lenvatinib mesylate: Oral, once daily

  • QLS5133; BevacizumabDrug

    Intravenous infusion,Q3W

  • QLS5133; Platinum; BevacizumabDrug

    Intravenous infusion,Q3W

  • QLS5133; Olaparib; BevacizumabDrug

    Olaparib is oral; all others are intravenous infusion,Q3W

  • QLS5133; QL2107; BevacizumabDrug

    Intravenous infusion,Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib Outcome 1:Incidence and severity of adverse events and serious adverse eventsTime frame: up to 2 years
  2. Phase Ib Outcome 2:Maximum tolerated dose (MTD)Time frame: 28 days
  3. Phase Ib Outcome 3:Recommended Phase 2 Dose (RP2D)Time frame: up to 2 years
  4. Phase II outcome 1:Objective response rate (ORR) (Arms 1B, 2B, 3B-3, 4B, 6B)Time frame: up to 2 years
  5. Phase II outcome 2:Progression-free survival (PFS) (Arms 3B-1, 3B-2, and 5B)Time frame: up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.